Zhongchao Inc. reports developments as a Cayman Islands holding company whose PRC operating entities provide platform-based healthcare information, education, training, patient management, and internet healthcare services in China. Its updates center on cancer and major-disease services, including the MDMOOC professional education platform, Zhongxin patient management programs, Zhixun Internet Hospital, and Sunshine Health Forums.
Recurring news themes include patient aid and medication assistance projects, disease management models for oncology and autoimmune conditions, healthcare professional education platforms, content partnerships for cancer education, and ordinary-share consolidations tied to Nasdaq listing compliance for ZCMD Class A ordinary shares.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its MDMOOC platform's online training course titled "Disease Prevention and Distribution Quality Management," aimed at enhancing skills in vaccination management for up to 20,000 healthcare staff. The course, launched in April 2022, is accessible through the MDMOOC website and WeChat platforms. Industry experts from various locations will lead the course, addressing key aspects of disease control and public health. Zhongchao remains committed to providing timely training for medical professionals in response to pandemic-related challenges.
Zhongchao Inc. (NASDAQ: ZCMD) reported a 94.6% decline in net income to $238,665 for the fiscal year 2021, down from $4.46 million in 2020. Revenues fell 9.4% to $16.30 million, primarily due to reduced income from medical training and education services. Gross profit also decreased by 20.5% to $9.44 million, leading to a gross margin decline of 8.1 percentage points. Operating expenses rose 32.2% to $9.76 million, driven by significantly increased general and administrative costs.
Zhongchao Inc. (NASDAQ: ZCMD) announced that its innovative patient management system has significantly improved the Duration of Therapy (DOT) by 40.4% for liver cancer patients. This improvement enhances drug efficiency and supports longer patient survival rates. The system aids nearly 20,000 patients in managing their treatment through education, follow-ups, and psychological support. With 400,000 new liver cancer cases reported in China in 2020, this advancement has the potential to notably impact patient outcomes and overall healthcare efficiency.
Zhongchao Inc. (NASDAQ: ZCMD) has launched the Hematology MDT Platform, an online training resource designed to enhance multidisciplinary treatment (MDT) skills for healthcare professionals. This platform facilitates real-time collaboration and problem-solving among physicians by providing access to expert guidance and training videos. As of August 2021, over 10,000 physicians have engaged with this platform, highlighting the growing demand for MDT in treating complex diseases like hematology within China. The company aims to expand this model across other medical areas to improve healthcare efficiency.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its Hematological Tumor Patient Care Center via its subsidiary, Shanghai Zhongxin Medical Technology. This initiative expands its services in tumor patient management to the out-of-hospital market, catering to nearly 10,000 hematological tumor patients. The Care Center provides comprehensive disease management, including patient education and personalized health assessments. With a projected rise in hematologic tumor cases in China, Zhongchao aims to enhance treatment experiences for patients through its innovative management services.
Zhongchao Inc. (NASDAQ: ZCMD) has expanded its patient management services for ovarian cancer through its subsidiary, Shanghai Zhongxin Medical Technology. This follows the Zeyoulexiang Patient Assistance Project, which aids patients requiring Niraparib. Utilizing their All-in-One System, over 5,000 patients have benefited since July 2021. The ovarian cancer market is projected to grow significantly, from $1.8 billion in 2018 to $6.7 billion by 2028. Zhongchao aims to capitalize on this growth by enhancing treatment outcomes and expanding its patient management operations.
Zhongchao Inc. (NASDAQ: ZCMD) has launched the Treatment Outcome Oriented DOT Management System through its subsidiary, Shanghai Zhongxin Medical Technology Co., Ltd. This innovative system aims to enhance patient management in the tumor and rare disease market by improving medication adherence and treatment outcomes. The DOT Management System assesses curative effects and predicts adverse reactions, providing tailored interventions for patients to ease their concerns. This launch positions Zhongchao to leverage expanding market opportunities in oncology drug management, fostering deeper collaborations with pharmaceutical companies.
Zhongchao Inc. (NASDAQ: ZCMD) announced that approximately 100,000 users utilized its Breast Cancer Tiered Diagnosis and Treatment Improvement Platform in H1 2021. With 2.5 million breast cancer patients in China, and 400,000 new cases annually, the Platform aims to enhance treatment accessibility, especially in underdeveloped areas. The market for breast cancer drugs in China was valued at 50.1 billion Yuan in 2020, expected to reach 73.9 billion Yuan by 2024. The initiative aligns with China's Healthy China 2030 Guideline to improve cancer survival rates.
Zhongchao Inc. (NASDAQ: ZCMD) has established a new subsidiary, Ningxia Zhongxin Internet Hospital Co., Ltd., to enhance its healthcare services. This initiative aims to strengthen patient management services by combining inpatient and outpatient care into an all-inclusive service. The new internet hospital will focus on improving patient treatment experiences and creating business opportunities through data sharing. The chairman noted a significant increase in demand for internet hospitals during the Covid-19 outbreak and cited new government guidelines as supportive of this growth.
Zhongchao Inc. (NASDAQ: ZCMD) has announced a collaboration with AbbVie Pharmaceutical Trading Co., Ltd. to enhance physician education in China.
This partnership focuses on developing medical education content and courses aimed at improving healthcare delivery. AbbVie is recognized for its innovations in immunology, oncology, and neuroscience. Zhongchao aims to leverage AbbVie's expertise to advance medical education services through its platforms.